Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats

Molecular and Cellular Biochemistry

Volumn 373, Issue 1-2, 2013, Pages 189-194

  Singh, Yogendra ^a   Singh, Kulwinder ^b   Sharma, P L ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b BABA FARID UNIVERSITY OF HEALTH SCIENCES   (India)

Author keywords

Aliskiren; AVE 0991; DOCA salt hypertension; Mas receptor

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; DEOXYCORTICOSTERONE ACETATE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE CUFF; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENTIATION; FEMALE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; TAIL CUFF METHOD; TREATMENT DURATION;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DESOXYCORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HYPERTENSION; IMIDAZOLES; MALE; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RENIN;

RATTUS;

EID: 84871766448     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1489-2     Document Type: Article

References (41)

1. Cheung BM, Ong KL, Man YB, Lam KS, Lau CP (2006) Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens 2:93-98
2. Pierdomenico SD, Di Nicola M, Esposito AL et al (2009) Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 22:842-847
3. Schmieder RE, Hilgers KF, Schlaich MP et al (2007) Renin-angiotensin system and cardiovascular risk. Lancet 369:1208-1219
4. Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153
5. Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14:S73-S86
6. Chappell MC, Iyer SN, Diz DI, Ferrario CM (1998) Antihypertensive effects of angiotensin-(1-7). Braz J Med Biol Res 31:1205-1212
7. Roks AJM, van Geel PP, Pinto YM et al (1999) Angiotensin-(1-7) is a modulator of the human rennin-angiotensin system. Hypertension 34:296-301
8. Collister JP, Hendel MD (2003) The role of Ang-(1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst 4:176-179
9. Donoghue M, Hsieh F, Baronas E et al (2000) A novel angiotensin- converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:E1-E9
10. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238-33243
11. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cells growth. Hypertension 28:104-108
12. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI (1997) Counter-regulatory actions of angiotensin-(1-7). Hypertension 30:535-541
13. Singh K, Singh T, Sharma PL (2011) Beneficial effect of angiotensin (1-7) in diabetic rats with cardiomyopathy. Ther Adv Cardiovasc Dis 5:159-167
14. Singh T, Singh K, Sharma PL (2010) Ameliorative potential of angiotensin (1-7)/Mas receptor axis in streptozotocin-induced diabetic nephropathy in the rat. Meth Find Exp Clin Pharmacol 32:19-25
15. Singh K, Sharma K, Singh M, Sharma PL (2012) Possible mechanism of cardio-reno protective effects of AVE0991, a nonpeptide Mas-receptor agonist in diabetic rats. J Renin Angiotensin Aldosterione Syst 13:334-340
16. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H (2002) AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40:847-852
17. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA (2005) The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. J Cardiovasc Pharmacol 46:274-279
18. Sealey JE, Laragh JH (2007) Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 20:587-597
19. Jensen C, Herold P, Brunner HR (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 7:310-399
20. Pilz B, Shagdarsuren E, Wellner M et al (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46:569-576
21. Takator LK, Ogura T, Ota Z (1991) Computerized approach using autoradiography to quantify atrial natriuretic peptide receptors in the DOCA-salt hypertensive rat kidney. Regul Pept 35:115-125
22. Montezano ACI, Callera GE, Mota AL et al (2005) Endothelin-1 contributes to the sexual differences in renal damage in DOCA-salt rats. Peptides 26:1454-1462
23. Cordellini S (1999) Endothelial dysfunction in DOCA-salt hypertension possible involvement of prostaglandin endoperoxides. Gen Pharmacol 32:315-320
24. Lastra G, Habibi J, Whaley-Connell AT et al (2009) Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue rennin overexpression. Endocrinology 150:2561-2568
25. Benter IF, Yousif MHM, Anim JT, Cojocel C, Diz DI (2006) Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with l-NAME. Am J Physiol Heart Circ Physiol 290:H684-H691
26. Young M, Head G, Funder J (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol Endocrinol Metab 269:E657-E662
27. Dobrzynski E, Wang C, Chao J, Chao L (2000) Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 36:995-1001
28. Fowler JD, Krueth SB, Bernlohr DA, Katz SA (2009) Renin dynamics in adipose tissue: adipose tissue control of local renin concentrations. Am J Physiol Endocrinol Metab 296:E343-E350
29. Tank JE, Moe OW, Star RA, Henrich WL (1996) Differential regulation of rat glomerular and proximal tubular renin mRNA following uninephrectomy. Am J Physiol 270:F776-F783
30. Rosivall L, Navar LG (1983) Effects on renal hemodynamics of intra-arterial infusions of angiotensins I and II. Am J Physiol 245:F181-F187
31. Liu FY, Cogan MG (1988) Angiotensin II stimulation of hydrogen ion secretion in the rat early proximal tubule: modes of action, mechanism, and kinetics. J Clin Invest 82:601-607
32. + ATPase in rat proximal straight tubules. J Am Soc Nephrol 1:1146-1152
33. Mitchell KD, Braam B, Navar LG (1992) Hypertensinogenic mechanisms mediated by renal actions of renin-angiotensin system. Hypertension 19:118-127
34. - cotransporter by angiotensin II in rabbit renal cortex. Am J Physiol 265:F195-F203
35. Wang T, Giebisch G (1996) Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am J Physiol 271:F143-F149
36. Stanton A, Jensen C, Nussberger J, O'Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42:1137-1143
37. McMurray JJC, Pitt B, Latine R, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators et al (2008) Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1:17-24
38. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 23:417-426
39. Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24:243-256
40. Koka V, Huang XR, Chung ACK, Wang W, Truong LD, Lan HY (2008) Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 175:1174-1183
41. Sullivan JC, Bhatia K, Yamamoto T, Elmarakby AA (2010) Angiotensin (1-7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats. Hypertension 56:658-666